Open AccessCorrelation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
Author(s) -
Junji Koyama,
Atsushi Horiike,
Takahiro Yoshizawa,
Yosuke Dotsu,
Ryo Ariyasu,
Masafumi Saiki,
Tomoaki Sonoda,
Ken Uchibori,
Shingo Nishikawa,
Satoru Kitazono,
Noriko Yanagitani,
Hironori Ninomiya,
Yuichi Ishikawa,
Makoto Nishio
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.04.102
Subject(s) - medicine , thyroid , thyroid transcription factor 1 , immune system , transcription factor , lung cancer , cancer research , thyroid cancer , lung , protein expression , cell , programmed cell death , oncology , thyroid dysfunction , pathology , immunology , cancer , apoptosis , gene , adenocarcinoma , biology , biochemistry , genetics
Recent studies have suggested a correlation between immune-related thyroid dysfunction (irTD) and the superior efficacy of anti-programmed cell death protein-1 (anti-PD-1) treatment in non-small cell lung cancer (NSCLC). Embryologically, the lung and thyroid are similar in origin, and thyroid transcription factor-1 (TTF-1) expresses in both organs, including NSCLC. We explored our hypothesis that TTF-1 expression in NSCLC might correlate with irTD incidence and anti-PD-1 treatment efficacy.